Drug intelligence / Profile preview

infliximab + sirolimus

Development stage: Preclinical
Lead developer: Janssen Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of infliximab, a TNF-α inhibitor monoclonal antibody, and sirolimus, an mTOR inhibitor. This dual therapy approach has been studied for treating severe steroid-refractory inflammatory bowel diseases, particularly ulcerative colitis and Crohn's disease. The combination leverages complementary mechanisms of action to potentially enhance efficacy in cases where conventional therapies have failed.

Targets

TNFA (Tumor necrosis factor alpha (soluble))Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on infliximab + sirolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on infliximab + sirolimus.

Explore the full profile